The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

AI Healthcare Stock Showing Signs of a Base Breakout
Source: John Newell (08/25/2025)

John Newell of John Newell & Associates explains why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy.

Co.'s Graphene Used in New Screening Test for Lung Cancer
Source: Streetwise Reports (08/18/2025)

HydroGraph Clean Power Inc.'s (HG:CSE; HGRAF:OTCQB; M98:FSE) patented, high-purity material has applications in healthcare, as in this case, but also in numerous other industries. Read on to learn why some experts say this company could be a future 100-bagger.

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Source: Dr. Douglas Loe (08/13/2025)

Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating.

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment
Source: Streetwise Reports (08/11/2025)

Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock.

Biotech Announces Topline Results From Cardiovascular Drug Trial
Source: Brandon Folkes (08/11/2025)

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis.